Purpose: Understanding the impact of fluid in different retinal compartments is critical to
developing treatment paradigms that optimize visual acuity and reduce treatment burden in …

Purpose To test the hypothesis that tolerating some subretinal fluid (SRF) in patients with
neovascular age-related macular degeneration (nAMD) treated with ranibizumab using a …

Introduction In neovascular age-related macular degeneration (nAMD) the exact amount of
fluid and its location on optical coherence tomography (OCT) have been defined as crucial …

Purpose To evaluate the relationship between retinal fluid location, amount/severity, and
vision with ranibizumab-treated neovascular age-related macular degeneration (nAMD) …

To evaluate the real-world treatment outcomes in patients with neovascular age-related
macular degeneration (nAMD) in Korea, focusing on retinal fluid resolution. This multi …

Purpose: Retinal fluid and thickness are important anatomical features of disease activity in
neovascular age-related macular degeneration, as evidenced by clinical trials that have …

Purpose: To investigate quantitative differences in fluid volumes between subretinal fluid
(SRF)–tolerant and SRF-intolerant treat-and-extend regimens for neovascular age-related …

Purpose To assess the effect of fluid status at baseline (BL) and at the end of the loading
phase (LP) of three different ranibizumab regimens: treat‐and‐extend (T&E), fixed bimonthly …

Purpose To investigate the functional associations of intraretinal fluid (IRF) and subretinal
fluid (SRF) volumes at baseline and after the loading dose as well as fluid change after the …

Age-related macular degeneration (AMD) is the third leading cause of blindness globally.
The burden is poised to increase as 3.7 million patients will be living with AMD by 2030 …